Low-cost, rapidly-developed, 3D printed in vitro corpus callosum model for mucopolysaccharidosis type I

Anthony Tabet, Matthew Gardner, Sebastian Swanson, Sydney Crump, Austin McMeekin, Diana Gong, Rebecca Tabet, Benjamin Hacker, Igor Nestrasil

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations


The rising prevalence of high throughput screening and the general inability of (1) two dimensional (2D) cell culture and (2) in vitro release studies to predict in vivo neurobiological and pharmacokinetic responses in humans has led to greater interest in more realistic three dimensional (3D) benchtop platforms. Advantages of 3D human cell culture over its 2D analogue, or even animal models, include taking the effects of microgeometry and long-range topological features into consideration. In the era of personalized medicine, it has become increasingly valuable to screen candidate molecules and synergistic therapeutics at a patient-specific level, in particular for diseases that manifest in highly variable ways. The lack of established standards and the relatively arbitrary choice of probing conditions has limited in vitro drug release to a largely qualitative assessment as opposed to a predictive, quantitative measure of pharmacokinetics and pharmacodynamics in tissue. Here we report the methods used in the rapid, low-cost development of a 3D model of a mucopolysaccharidosis type I patient's corpus callosum, which may be used for cell culture and drug release. The CAD model is developed from in vivo brain MRI tracing of the corpus callosum using open-source software, printed with poly (lactic-acid) on a Makerbot Replicator 5X, UV-sterilized, and coated with poly (lysine) for cellular adhesion. Adaptations of material and 3D printer for expanded applications are also discussed.

Original languageEnglish (US)
Article number2811
StatePublished - 2016

Bibliographical note

Funding Information:
The authors thank Nicholas Powley, Mac Cameron, and Heather Fong for encouragement in pursuing this project. The MRIs were provided from the projected funded by Lysosomal Disease Network (RDCRN; grant number NIH U54NS065768). Parts of this work were funded by a CoCreate Community Research Grant (#16354).

Publisher Copyright:
© 2016 Tabet A et al.


  • 3D printing
  • Cell culture
  • Corpus callosum
  • In vitro release
  • Mucopolysaccharidosis
  • Neurodegenerative disease


Dive into the research topics of 'Low-cost, rapidly-developed, 3D printed in vitro corpus callosum model for mucopolysaccharidosis type I'. Together they form a unique fingerprint.

Cite this